Stifel Nicolaus reissued their hold rating on shares of Tilray (NASDAQ:TLRY) in a research note issued to investors on Wednesday, The Fly reports.
Several other research firms have also commented on TLRY. Zacks Investment Research raised Tilray from a hold rating to a buy rating and set a $48.00 price objective on the stock in a research report on Tuesday, August 13th. Compass Point cut their price objective on Tilray from $41.00 to $38.00 and set a sell rating on the stock in a research report on Monday, June 17th. Oppenheimer started coverage on Tilray in a research report on Tuesday, June 4th. They issued a market perform rating on the stock. Alliance Global Partners started coverage on Tilray in a research report on Monday, May 13th. They issued a neutral rating and a $50.00 price objective on the stock. Finally, Northland Securities reissued a hold rating on shares of Tilray in a research report on Wednesday. Four research analysts have rated the stock with a sell rating, nine have given a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of Hold and an average target price of $67.24.
Shares of Tilray stock opened at $31.31 on Wednesday. Tilray has a twelve month low of $28.88 and a twelve month high of $300.00. The stock has a market capitalization of $3.80 billion and a P/E ratio of -38.18. The company has a current ratio of 2.04, a quick ratio of 2.06 and a debt-to-equity ratio of 1.21. The business’s fifty day moving average price is $43.53 and its 200 day moving average price is $54.88.
Tilray (NASDAQ:TLRY) last issued its earnings results on Tuesday, August 13th. The company reported ($0.32) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.09). Tilray had a negative net margin of 121.73% and a negative return on equity of 37.64%. The firm had revenue of $45.90 million during the quarter, compared to analyst estimates of $40.25 million. During the same quarter in the previous year, the business posted ($0.17) EPS. Tilray’s revenue was up 373.2% compared to the same quarter last year. As a group, sell-side analysts predict that Tilray will post -0.98 EPS for the current year.
In other news, Director Christine St.Clare sold 4,000 shares of Tilray stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of $50.01, for a total transaction of $200,040.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 3.40% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Lee Financial Co purchased a new stake in shares of Tilray during the first quarter worth about $25,000. Quantamental Technologies LLC bought a new stake in Tilray in the first quarter valued at about $26,000. PNC Financial Services Group Inc. increased its holdings in Tilray by 105.8% in the first quarter. PNC Financial Services Group Inc. now owns 463 shares of the company’s stock valued at $30,000 after buying an additional 238 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Tilray in the second quarter valued at about $46,000. Finally, Certified Advisory Corp increased its holdings in Tilray by 152.1% in the second quarter. Certified Advisory Corp now owns 1,041 shares of the company’s stock valued at $48,000 after buying an additional 628 shares during the last quarter. 2.28% of the stock is currently owned by institutional investors and hedge funds.
Tilray Company Profile
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Recommended Story: What are different types of coverage ratios?
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.